Pure Global
NCT06413381

RISK FACTORS FOR NON-RESPONSE TO HORMONAL MEDICAL THERAPY IN PATIENTS WITH ENDOMETRIOSIS

IRCCS Azienda Ospedaliero-Universitaria di Bologna·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Endometriosis
Study type
Observational
Sponsor & location
Primary sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Location
Bologna, Italy
Timeline & enrollment
Phase
N/A
Start date
Apr 19, 2024
End date
Nov 28, 2029
Enrollment
250 participants
Primary outcome

Rate of patients with endometriosis non-responsive to medical treatment at 12 months

Summary

Determine the proportion of patients with endometriosis unresponsive to medical therapy and
 to compare the clinical and ultrasonographic characteristics of this group of patients (study
 group) with the clinical and ultrasonographic characteristics of patients responsive to
 medical therapy (control group).

ICD-10 classifications
EndometriosisOther endometriosisEndometriosis, unspecifiedEndometriosis of uterusEndometriosis of ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06413381
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06413381 through Pure Global AI's free database. This phase not specified trial is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna and is currently Recruiting. The study focuses on Endometriosis. Target enrollment is 250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.